Brought to you by 
Merck licenses NMDA receptor antagonist MK0657 to Cerecor
30 Apr 2013
Executive Summary
Merck & Co. Inc. has granted Cerecor Inc. (developing drugs that act in the nervous system) exclusive worldwide rights to its MK0657, an oral N-methyl-D-aspartate (NMDA) glutamate receptor subunit 2B (NR2B) antagonist, for all indications including depression.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck licenses NMDA receptor antagonist MK0657 to Cerecor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice